As the number of oligo therapeutics in development continues to increase, so too does their complexity, the scale of oligo manufacturing to support late-stage development and commercialization ...

A new platform for making oligonucleotides offers chemists a way to plug in five types of nucleoside connections, so they can tailor properties of oligonucleotide therapeutics. These short DNA or ...

Eli Lilly is paying $13 million upfront, with $1 billion in biobucks up for grabs, for the opportunity to develop AI-designed oligonucleotide therapies from Creyon Bio.

- The next frontier in oligonucleotide synthesis is the direct synthesis of gene-length sequences. - Ansa synthesized a 1005 base long oligonucleotide with industry-leading accuracy. - Ansa will ...

Agilent Technologies says it will spend $725 million to double its manufacturing capacity for therapeutic nucleic acids, or oligonucleotides. The project is the latest in a round of industry ...

The global oligonucleotide therapy market is witnessing impressive growth, expected to rise from $1.1 billion in 2022 to $1.23 billion in 2023, at a compound annual growth rate (CAGR) of 12.2% ...

Nitto Denko Avecia Inc. is a leader in oligonucleotide therapeutic manufacturing and development services with facilities located in Milford (Massachusetts) and Cincinnati (Ohio).

Acquisition positions AlphaRose as a leader in next generation Antisense Oligonucleotide Therapeutics with a novel proprietary oligonucleotide chemistry (abcDNA) platform invented at University of ...

Scientists have developed a new approach to produce life-saving oligonucleotide therapeutics on a large scale, in high purity, and with minimal environmental impacts.

If binding affinity is sufficiently high, annealing of the antisense compound can block interaction of the RNA with proteins, changing the biological function of that RNA.